Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 6/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9283251 | 0.91 | BRD4 (0.44) | BRD4CREBBPATMPTGS1PTGS2 | |
| SCHEMBL9281041 | 0.80 | BRD4 (0.41) | BRD4CREBBPATMALDH1A1 | |
| SCHEMBL13263176 | 0.72 | HEXA (0.50) | BRD4ATMPTGS1PTGS2ALDH1A1 | |
| SCHEMBL4191435 | 0.67 | GAA (0.53) | BRD4ATMALDH1A1 | |
| SCHEMBL9973964 | 0.66 | ERN1 (0.39) | BRD4PTGS1PTGS2ALDH1A1 | |
| SCHEMBL16303813 | 0.64 | BRD4 (0.38) | BRD4ATM | |
| SCHEMBL9281485 | 0.64 | MAPT (0.43) | BRD4ATMGPBAR1ALDH1A1 | |
| Alcohol SCHEMBL10905333 | 0.64 | CA1 (0.49) | BRD4ATMALDH1A1 | |
| SCHEMBL4082510 | 0.63 | TSHR (0.58) | BRD4ATMALDH1A1 | |
| SCHEMBL30986710 | 0.63 | TSHR (0.58) | BRD4ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8796261-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | BRD4 1/4885CREBBP 26/4885ATM 2477/4885 |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | BRD4 1/4885CREBBP 26/4885ATM 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.